Trizivir (AZT/3TC/Abacavir)
| Brand Name: |
Trizivir |
| Generic Name: |
Zidovudine/ lamivudine/ abacavir, AZT/3TC/ABC |
| Adult Single Dose: |
One tablet containing 300 mg AZT,
150 mg 3TC and 300 mg ABC (twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- Trizivir (Zidovudine + Lamivudine + Abacavir) (November 3, 2010)
To read PDF, click here.
From AIDS InfoNet
- Trizivir (March/April 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Trizivir (AZT/3TC/Abacavir) (PDF) (March 2009)
From GlaxoSmithKline
- An Overview of Trizivir (AZT/3TC/Abacavir) (February 19, 2009)
From AIDSinfo
- Trizivir (AZT + Epivir + Ziagen) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Trizivir (AZT/3TC/Abacavir) (August 15, 2006)
From AIDS Treatment Data Network
- Drug Interactions: Trizivir (August 2004)
[Archived Article]
From Project Inform
- EU Approves GlaxoSmithKline's HIV Triple Therapy Trizivir (January 4, 2001)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Approves Videx EC and Trizivir (November 27, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- "Trizivir" Approved: Three Existing Drugs in One (November 17, 2000)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Trizivir for HIV (November 15, 2000)
[Archived Article]
From U.S. Food and Drug Administration
Research
- The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir? (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV JournalView: Induction-Maintenance With Zidovudine/Lamivudine/Abacavir (July/August 2005)
[Archived Article]
A much-maligned triple-NRTI combo gets a second look as part of a simplification strategy.
In HIV Treatment ALERTS!, from The Body PRO
- A5095 and the Triple-Nucleoside Saga (January 2005)
[Archived Article]
A second look at the study that -- at the time -- appeared to doom Trizivir; part of HIV JournalView's Top 10 Research Reports of 2004.
In AIDS Treatment News, from The Body PRO
- Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
[Archived Article]
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine
- Keeping It Real: Don't Believe Everything You Read (October 2003)
[Archived Article]
Do the recently revealed limitations of Trizivir make it "dangerous"?.
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
- Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
[Archived Article]
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- We Want Our Trizivir! (September/October 2003)
[Archived Article]
IAS 2003 attendees defend the use of Trizivir at the presentation on ACTG 5095.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- AIDS Healthcare Foundation Asks FDA to Withdraw Approval of GSK's Antiretroviral Drug Trizivir (August 20, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Is Trizivir Plus Tenofovir Effective in Patients With Possible or Proven Reverse Transcriptase Resistance? (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Another Look at Induction Maintenance Therapy (July 14, 2003)
[Archived Article]
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Trizivir Often Successful in Treatment-Naive Patients; Resistance Testing Key for Failures (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
[Archived Article]
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Abacavir Arm Stopped in Clinical Trial (April 4, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- AIDS Drug in Halted Trial Is Less Effective Taken Alone (March 13, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
[Archived Article]
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here.
From U.S. National Institute of Allergy and Infectious Diseases
- Dear Healthcare Provider Letter From the Division of AIDS -- Concern About Trizivir Potency (Spring 2003)
[Archived Article]
Recap from Jeffrey T. Schouten, M.D., one of the A5095 study's investigators.
In STEP Perspective, from Seattle Treatment Education Project
- Efficacy and Safety of AZT/3TC/ABC (Trizivir) Maintenance Treatment After First-Line Quadruple Induction Therapy; Interim 24-Week Data From AZLF3004/TRISUD (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Efficacy of Quad Therapy in Antiretroviral-Naive Adults With Very Low CD4 Cell Counts: The Tetra Study (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Shift in HIV-1 Resistance After Treatment Interruption in Patients With Virological Failure and Antiviral Effect Following Trizivir Plus Efavirenz (AZLF3003 Study) (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Trizivir Preferred Over Continued HAART in HIV-Infected Patients (March/April 2002)
TRIZAL study results; highlights from ICAAC 2002.
In Body Positive, from Body Positive
- CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002) (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Comparison of the Metabolic Disorders and Clinical Lipodystrophy 48 Weeks After Switching From HAART to Trizivir Versus Continued HAART (TRIZAL: AZL30002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Protease Inhibitor Class-Sparing Maintenance Therapy With Abacavir (ABC) + Lamivudine (3TC) + Zidovudine (ZDV) in Patients With Long-Term Suppression of HIV-1 RNA (February 2000)
From Seattle Treatment Education Project
|
|
Advertisement
|
Email
Glossary
